Human Medicine - Oncology

Abstract O. Hermine Industry’s Perspective 2016

01/07/2016 – Development of masitinib, a novel tyrosine kinase inhibitor and immunotherapeutic, for the treatment of peripheral T-cell lymphoma
Expert Opinion on Orphan Drugs May 2016

01/05/2016 – Masitinib for gastrointestinal stromal tumors
Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia November 2015

01/11/2015 –

Rapid and clinically significant response to masitinib in the treatment of mucosal primary esophageal melanoma with somatic KIT exon 11 mutation involving brain metastases:
European Journal of Cancer September 2015

01/09/2015 –

Masitinib plus FOLFIRI for second-line treatment of metastatic colorectal cancer: 2-year follow-up of phase 2, open label trial
Annal Onco (IN PRESS) 2015 Deplanque-MASITINIB PANCREATIC CANCER P3

09/04/2015 – A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer
ASCO 2012 Le Cense-MASITINIB 1st LINE GIST 5Y

25/07/2014 – Masitinib in imatinib-naive advanced gastrointestinal stromal tumor (GIST): Five year follow-up of the French Sarcoma Group phase II trial.
Le Cesne-Annals Onco 2014-GISTL2 ph2 results

25/07/2014 – Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial
Eur J Haematol 2012 Georgin-Lavialle-MASITINIB IN MAST CELL LEUKEMIA

19/01/2012 – Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor
Overall survival benefit with masitinib mesylate in imatinibnaive, locally advanced, or metastatic GIST

24/01/2011 – 4-years follow-up of the French Sarcoma Group phase II trial.
Eur J Cancer 2009 Soria-MASITINIB IN SOLID CANCERS P1

07/05/2009 – Phase 1 dose-escalation study of oral tyrosine kinase inhibitor Masitinib in advanced and/or metastatic solid cancers

Human Medicine – Oncology

Related Posts